Experimental evidence accumulated over decades has implicated epithelial–mesenchymal
plasticity (EMP), which collectively encompasses epithelial–mesenchymal transition and the …

Epithelial-to-mesenchymal transition (EMT) mechanism is responsible for metastasis and
migration of cancer cells to neighboring cells and tissues. Morphologically, epithelial cells …

Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

Epithelial-to-mesenchymal transition (EMT) determines the most lethal features of cancer,
metastasis formation and chemoresistance, and therefore represents an attractive target in …

The success of next-generation androgen receptor (AR) pathway inhibitors, such as
abiraterone acetate and enzalutamide, in treating prostate cancer has been hampered by …

Despite advances in cancer biology and therapeutics, drug resistance remains problematic.
Resistance is often multifactorial, heterogeneous, and prone to undersampling …

CD44, a multi-structural and multifunctional transmembrane glycoprotein, was initially
identified as a receptor for hyaluronan that participates in both physiological and …

Docetaxel is the first-line chemotherapy agent for metastatic prostate cancer. However, the
emergence of resistance diminishes its efficacy and limits the survival benefit. Quercetin is a …

Epithelial-mesenchymal transition (EMT) is a cellular process by which epithelial cells lose
their characteristics and acquire mesenchymal traits to promote cell movement. This …

Simple Summary Drug resistance is prevalent in many types of cancer and decreases
patient survival. The taxanes are anti-mitotic chemotherapeutic agents, widely used since …